← Back to Search
Antiretroviral Agent
AntiRetroviral Therapy for Alzheimer's Disease (ART-AD Trial)
San Antonio, TX
Phase 1 & 2
Waitlist Available
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Creatinine clearance test (CrCl) ≥ 50 mL/min
Clinical diagnosis of early Alzheimer's disease (Clinical Dementia Rating (CDR) = 0.5, Mini-Mental State Exam (MMSE) = 24-30)
Must not have
Diagnosis of HIV infection or AIDS (CD4 count < 200), HIV/Hepatitis B Virus (HBV) co-infection, HBV or human T-cell leukemia virus infection
Current use of memantine or sorbitol-containing products
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial will test a new drug for Alzheimer's disease to see if it can penetrate the brain, suppress neurodegeneration, and is safe and tolerated by patients.
See full description
Who is the study for?
This trial is for people aged 50-99 with early Alzheimer's (CDR=0.5, MMSE=24-30). They must have stable medication doses if treating Alzheimer's symptoms, normal liver and kidney function tests, controlled cholesterol and glucose levels, no significant psychiatric issues or substance abuse in the past six months, and not be planning to travel during the study.Check my eligibility
What is being tested?
The study is testing a drug called 3TC on patients with early-stage Alzheimer's disease. It aims to see if this drug can target brain changes related to Alzheimer’s, slow down neurodegeneration, enter the central nervous system effectively and determine its safety.See study design
What are the potential side effects?
While specific side effects of 3TC in this context are not listed here, common ones may include digestive issues like nausea or diarrhea; fatigue; headaches; coughing; general body discomforts such as muscle pain.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidneys are functioning well, with a creatinine clearance rate of 50 mL/min or higher.
show original
Select...
I have been diagnosed with early Alzheimer's disease.
show original
Select...
I am between 50 and 99 years old.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have HIV/AIDS, HBV, or human T-cell leukemia virus.
show original
Select...
I am currently using memantine or products containing sorbitol.
show original
Select...
I do not have brain bleeding, bleeding disorders, or abnormal brain vessels.
show original
Select...
I have not had a stroke, mini-stroke, or unexplained fainting in the last 6 months.
show original
Select...
I have hearing, vision, or movement issues that could affect my trial participation.
show original
Select...
I have had problems with my kidney or liver function.
show original
Select...
I have a condition other than Alzheimer's that could affect my thinking.
show original
Select...
My diabetes is not under control, or I am currently using insulin.
show original
Select...
I have HIV or HBV, or I've used specific HIV medications.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
3TC CNS Penetration
Change in Reverse Transcriptase Activity From Baseline to 24 Weeks in Plasma of Study Participants
Secondary study objectives
Change in Dementia Severity From Baseline to Week 24 of Treatment Based on the PACC-5 Z-score
Incidence of Treatment-Emergent Abnormal Vital Signs
Incidence of Treatment-Emergent Adverse Events
Side effects data
From 2018 Phase 3 trial • 167 Patients • NCT0261678311%
Nasopharyngitis
8%
Back pain
7%
Diarrhoea
6%
Vitamin D deficiency
6%
Hypertension
5%
Arthralgia
5%
Cough
4%
Bronchitis
4%
Urinary tract infection
1%
Cardiac arrest
1%
Pneumonia
1%
Sepsis
1%
Joint swelling
1%
Colorectal cancer
1%
Hepatocellular carcinoma
1%
Loss of consciousness
1%
Renal colic
1%
Prostatomegaly
1%
Escherichia sepsis
1%
Osteonecrosis
1%
Neuritis cranial
1%
Syncope
1%
Acute coronary syndrome
1%
Cholecystitis acute
1%
Acute kidney injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
E/C/F/TAF
Stay on Baseline Regimen
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Open-Label 3TCExperimental Treatment1 Intervention
12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
3TC
2005
Completed Phase 3
~390
Find a Location
Closest Location:Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases· San Antonio, TX
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
484 Previous Clinical Trials
92,030 Total Patients Enrolled
Owens Medical Research FoundationOTHER
Bess Frost, PhDLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have HIV/AIDS, HBV, or human T-cell leukemia virus.I am currently using memantine or products containing sorbitol.I haven't had a heart attack, severe heart failure, or major heart issues in the last 6 months.I do not have brain bleeding, bleeding disorders, or abnormal brain vessels.My Alzheimer's medication dose has been stable for at least 8 weeks.I have not had a stroke, mini-stroke, or unexplained fainting in the last 6 months.Your liver function tests show results that are no more than double the normal range.I have hearing, vision, or movement issues that could affect my trial participation.Your cholesterol, triglycerides, and blood sugar levels are within specific limits.Your blood pressure is not well controlled (systolic BP > 160, diastolic BP > 90 mmHg).My kidneys are functioning well, with a creatinine clearance rate of 50 mL/min or higher.Your blood clotting tests are normal.I have had problems with my kidney or liver function.You have had problems with alcohol or drug use in the past six months.You have enough white blood cells, neutrophils, platelets, and hemoglobin in your blood.I have been diagnosed with early Alzheimer's disease.I have a condition other than Alzheimer's that could affect my thinking.Your body mass index (BMI) is between 19 and 35.I am between 50 and 99 years old.I have not had a serious illness or infection in the last 30 days.My diabetes is not under control, or I am currently using insulin.I have HIV or HBV, or I've used specific HIV medications.
Research Study Groups:
This trial has the following groups:- Group 1: Open-Label 3TC
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.